Anticoagulant Reversal Drugs Market Analysis and Strategies of Key Players: Octapharma AG; China Biologic Products, Grifols, Shanghai RAAS Blood Products

Anticoagulant reversal drugs are required to reverse the effect of anticoagulation in certain situations such as unplanned surgery, overdose of anticoagulant therapy, and uncontrolled bleeding. Anticoagulant reversal drugs are used in medical conditions such as venous thromboembolism, atrial fibrillation (AF), mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome and Factor V Leiden. The growth of the anticoagulant reversal drug market growth is mainly attributed to the factors such as rising prevalence of atrial fibrillation (AFib) and stroke. However, the high cost of anticoagulant reversal drugs is restricting the market growth.

Boehringer Ingelheim International GmbH; Pfizer Inc; Octapharma AG; Amag Pharmaceuticals, Inc; Fresenius Kabi AG; Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals); CSL Limited; China Biologic Products, Inc; Grifols, S.A; and Shanghai RAAS Blood Products Co., Ltd are among the key companies in the anticoagulant reversal drugs market.  

Download sample PDF Copy @  https://www.theinsightpartners.com/sample/TIPRE00004954/

Based on distribution channel, the anticoagulant reversal drugs market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and is estimated to register the highest CAGR in the market during the forecast period. Hospital pharmacies offer complex and specialized medicines, which may not be available in a retail pharmacy. It ensures the availability of right medication, in the right dose and at the right time. These factors are expected to contribute to the growth of the market during the forecast period.

Oral anticoagulants are widely used and are highly effective in preventing thromboembolism among AFib patients. However, the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent bleeding.

As per the Centers for Disease Control and Prevention (CDC), in 2018, in the US, AFib was mentioned on around 175,326 death certificates and was the primary cause of death in about 25,845 of those deaths. Additionally, it has also anticipated that 12.1 million people in the US will have AFib by 2030.

Moreover, according to the European Society of Cardiology (ESC), in 2016, 7.6 million people above 65 years of age in the EU had atrial fibrillation and it is expected that the number will increase by 89% to reach 14.4 million by 2060. Similarly, as per the Stroke Association: State of the Nation 2017, more than 1 million people in the UK suffer from atrial fibrillation.

The report segments global anticoagulant reversal drugs market as follows:

By Product

• Prothrombin Complex Concentrates
• Vitamin K
• Protamine
• Tranexamic Acid
• Idarucizumab
• AndeXXa

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00004954/

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com